Status:

TERMINATED

Near-infrared Spectroscopy and Electroencephalography to Assess Cortical Activation During Motor Tasks in Infants and Toddlers With and Without Cerebral Palsy

Lead Sponsor:

National Institutes of Health Clinical Center (CC)

Conditions:

Autism

Cerebral Palsy

Eligibility:

All Genders

3-5 years

Brief Summary

Background: New ways to study the brain as people move include near-infrared spectroscopy (NIRS) and electroencephalography (EEG). NIRS uses laser light shone through the scalp to look at blood flow ...

Detailed Description

OBJECTIVE Portable neural imaging during functional tasks is now possible utilizing noninvasive near-infrared spectroscopy (NIRS) which identifies areas of brain activity by measuring blood flow dyna...

Eligibility Criteria

Inclusion

  • INCLUSION CRITERIA:
  • All subjects must be between age 3 months up to 5 years of age.
  • A healthy volunteer, or
  • A child with or at high risk for CP or ASD:
  • An infant/child with an established diagnosis of CP, or
  • An infant less than 18 months who has been identified by a physician as being at high risk for having CP, or
  • An infant/child with an established diagnosis of ASD or
  • A child less than 3 years of age who has been deemed at high-risk for ASD or developmental delays by a physician, early intervention specialist (enrolled in early intervention services), or other qualified health professional, or
  • A younger sibling to a child diagnosed with ASD
  • EXCLUSION CRITERIA:
  • Has any injury or health condition other than CP or ASD or being at-risk for having CP or ASD that affects the ability to move a body part repetitively for short periods. Examples include spinal cord injury, muscle diseases, congestive heart failure, or recently broken bones. The physician or other qualified health professioinal will discuss the child s health history during the screening to determine if participation is safe.
  • Child of investigators and children of subordinates to an investigator
  • Has a known genetic disorder that is a direct cause of the developmental delays
  • Additional exclusion criteria for infants and young children with or at high risk for CP:
  • Concurrent use of medicines for muscle tone (e.g., baclofen, trihexyphenedyl, dantrolene sodium, tizanidine, or carbidopa/levodopa).
  • Has had surgery involving the musculoskeletal system (bone, joints, tendons, muscles, or neurological system (brain, spinal cord, peripheral nerves) within the past year
  • Botulinum toxin injections within the past four months.
  • A history of having had a major seizure or now diagnosed as having a seizure disorder and is on medication for seizures (e.g. may have had a mild seizure(s) in the past but is not currently being treated for seizures).
  • Chronic respiratory problems that require the use of oxygen.
  • Additional exclusion criteria for infants and young children with or at high-risk for ASD:
  • Has had surgery involving the musculoskeletal system (bone, joints, tendons, muscles, or neurological system (brain, spinal cord, peripheral nerves) within the past year.
  • Has uncontrollable seizures (e.g. unable to be managed with medicines or treatment).
  • Additional exclusion criteria for infants and young children with TD
  • Born preterm (defined as less than 36 weeks gestation); or birth weight significantly below normal for gestational age (SGA- small for
  • gestational age).

Exclusion

    Key Trial Info

    Start Date :

    May 16 2018

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    August 21 2025

    Estimated Enrollment :

    26 Patients enrolled

    Trial Details

    Trial ID

    NCT03434080

    Start Date

    May 16 2018

    End Date

    August 21 2025

    Last Update

    August 22 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    National Institutes of Health Clinical Center

    Bethesda, Maryland, United States, 20892